TILs（Tumor Infiltrating Lymphocytes）

Phase 2Cell therapy

SShanghai OriginCell Therapeutics Co., Ltd.

TILs（Tumor Infiltrating Lymphocytes） is one of 55 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

TILs（Tumor Infiltrating Lymphocytes）

SShanghai OriginCell Therapeutics Co., Ltd.

Phase 2

1 9

Remeron

OOrganon and Co

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Lung Cancer

NCT06455917

Clinical

Trials by Indication[1]

Lung Cancer1 trial

TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT06455917·30 enrolled

Non-Small Cell Lung Cancer1 trial

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

Unknown status·SShanghai OriginCell Therapeutics Co., Ltd.·Phase 1·NCT04919616·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TILs（Tumor Infiltrating Lymphocytes）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TILs（Tumor Infiltrating Lymphocytes） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TILs（Tumor Infiltrating Lymphocytes）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai OriginCell Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SShanghai OriginCell Therapeutics Co., Ltd.

TILs（Tumor Infiltrating Lymphocytes）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News